388 related articles for article (PubMed ID: 18059220)
1. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients.
Williams MD; Roberts D; Blumenschein GR; Temam S; Kies MS; Rosenthal DI; Weber RS; El-Naggar AK
Am J Surg Pathol; 2007 Nov; 31(11):1645-52. PubMed ID: 18059220
[TBL] [Abstract][Full Text] [Related]
2. Expression of mitotic checkpoint proteins BUB1B and MAD2L1 in salivary duct carcinomas.
Ko YH; Roh JH; Son YI; Chung MK; Jang JY; Byun H; Baek CH; Jeong HS
J Oral Pathol Med; 2010 Apr; 39(4):349-55. PubMed ID: 20040022
[TBL] [Abstract][Full Text] [Related]
3. Novel estrogen receptor coactivator PELP1/MNAR gene and ERbeta expression in salivary duct adenocarcinoma: potential therapeutic targets.
Vadlamudi RK; Balasenthil S; Sahin AA; Kies M; Weber RS; Kumar R; El-Naggar AK
Hum Pathol; 2005 Jun; 36(6):670-5. PubMed ID: 16021574
[TBL] [Abstract][Full Text] [Related]
4. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases.
Jaehne M; Roeser K; Jaekel T; Schepers JD; Albert N; Löning T
Cancer; 2005 Jun; 103(12):2526-33. PubMed ID: 15900577
[TBL] [Abstract][Full Text] [Related]
5. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma.
Kapadia SB; Barnes L
Mod Pathol; 1998 Nov; 11(11):1033-8. PubMed ID: 9831198
[TBL] [Abstract][Full Text] [Related]
6. Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland.
Yamamoto H; Uryu H; Segawa Y; Tsuneyoshi M
Pathol Int; 2008 May; 58(5):322-6. PubMed ID: 18429833
[TBL] [Abstract][Full Text] [Related]
7. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification.
Elliott DD; Sherman SI; Busaidy NL; Williams MD; Santarpia L; Clayman GL; El-Naggar AK
Hum Pathol; 2008 Jan; 39(1):15-20. PubMed ID: 17949783
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas.
Ettl T; Schwarz S; Kleinsasser N; Hartmann A; Reichert TE; Driemel O
Histopathology; 2008 Nov; 53(5):567-77. PubMed ID: 18983466
[TBL] [Abstract][Full Text] [Related]
9. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
[TBL] [Abstract][Full Text] [Related]
10. Acinic cell carcinoma of minor salivary glands: a clinical and immunohistochemical study.
Triantafillidou K; Iordanidis F; Psomaderis K; Kalimeras E
J Oral Maxillofac Surg; 2010 Oct; 68(10):2489-96. PubMed ID: 20678839
[TBL] [Abstract][Full Text] [Related]
11. Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases.
Lewis JE; Olsen KD; Sebo TJ
Hum Pathol; 2001 Jun; 32(6):596-604. PubMed ID: 11431714
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor immunoexpression evaluation in malignant salivary gland tumours.
Monteiro LS; Bento MJ; Palmeira C; Lopes C
J Oral Pathol Med; 2009 Jul; 38(6):508-13. PubMed ID: 19317849
[TBL] [Abstract][Full Text] [Related]
13. Salivary duct carcinoma cytologically diagnosed distinctly from salivary gland carcinomas with squamous differentiation.
Kawahara A; Harada H; Akiba J; Kage M
Diagn Cytopathol; 2008 Jul; 36(7):485-93. PubMed ID: 18528886
[TBL] [Abstract][Full Text] [Related]
14. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
15. Intensity of androgen and epidermal growth factor receptor immunoreactivity in samples of radical prostatectomy as prognostic indicator: correlation with clinical data of long-term observations.
Schäfer W; Funke PJ; Kunde D; Rausch U; Wennemuth G; Stützer H
J Urol; 2006 Aug; 176(2):532-7. PubMed ID: 16813883
[TBL] [Abstract][Full Text] [Related]
16. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
[TBL] [Abstract][Full Text] [Related]
17. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
[TBL] [Abstract][Full Text] [Related]
18. Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast.
Lee Y; Cho S; Seo JH; Shin BK; Kim HK; Kim I; Kim A
Am J Clin Pathol; 2007 Dec; 128(6):1041-9. PubMed ID: 18024331
[TBL] [Abstract][Full Text] [Related]
19. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.
Di Palma S; Simpson RH; Marchiò C; Skálová A; Ungari M; Sandison A; Whitaker S; Parry S; Reis-Filho JS
Histopathology; 2012 Oct; 61(4):629-43. PubMed ID: 22882517
[TBL] [Abstract][Full Text] [Related]
20. Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma.
Pfannschmidt J; Bade S; Hoheisel J; Muley T; Dienemann H; Herpel E
Thorac Cardiovasc Surg; 2009 Oct; 57(7):403-8. PubMed ID: 19795327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
